Steminent Biotherapeutics, Inc.(TW:7729)
NT$247.00+17.50 (+7.63%)
TW:7729
Steminent Biotherapeutics, Inc. financials statements
NT$247.00
At close:+17.50 (+7.63%)
Steminent Biotherapeutics, Inc. (7729) Ratios
Steminent Biotherapeutics, Inc. Ratios
TW:7729's free cash flow for Q2 2026 was NT$-111.94M. For the 2026 fiscal year, TW:7729's free cash flow was decreased by NT$-2.02M and operating cash flow was NT$-109.92M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.58 | 7.43 | 12.07 | 6.68 | 10.79 |
| Quick Ratio | 13.18 | 7.05 | 11.87 | 6.54 | 10.33 |
| Cash Ratio | 13.09 | 6.47 | 11.69 | 6.36 | 10.25 |
| Solvency Ratio | -1.47 | -1.74 | -1.16 | -1.05 | -3.20 |
| Operating Cash Flow Ratio | -3.47 | -4.39 | -2.97 | -2.87 | -2.45 |
| Short-Term Operating Cash Flow Coverage | -32.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 420.51M | NT$ 153.79M | NT$ 365.57M | NT$ 89.04M | NT$ 207.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.15 | 0.13 | 0.23 | 0.07 |
| Debt-to-Equity Ratio | 0.13 | 0.18 | 0.15 | 0.34 | 0.08 |
| Debt-to-Capital Ratio | 0.11 | 0.15 | 0.13 | 0.25 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.16 | 1.23 | 1.20 | 1.44 | 1.14 |
| Debt Service Coverage Ratio | -22.96 | -73.32 | -64.75 | -83.68 | -84.12 |
| Interest Coverage Ratio | -80.26 | -84.75 | -73.77 | -109.37 | -57.01 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.35 | 1.18 | 1.73 | 1.26 | 0.58 |
| Net Debt to EBITDA | 2.95 | 1.01 | 3.26 | 1.31 | 1.90 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -110.10% | -1404.09% | -82.32% |
| EBIT Margin | 0.00% | 0.00% | -13543.78% | -13298.11% | -5793.26% |
| EBITDA Margin | 0.00% | 0.00% | -12262.17% | -11815.72% | -5258.98% |
| Operating Profit Margin | 0.00% | 0.00% | -13970.14% | -15442.14% | -3564.12% |
| Pretax Profit Margin | 0.00% | 0.00% | -13733.16% | -13439.31% | -5855.78% |
| Net Profit Margin | 0.00% | 0.00% | -13733.16% | -13439.31% | -5855.78% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -13733.16% | -13439.31% | -5855.78% |
| Net Income Per EBT | 99.94% | 100.09% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.74% | 97.73% | 98.30% | 87.03% | 164.30% |
| Return on Assets (ROA) | -24.92% | -36.35% | -21.76% | -36.27% | -44.44% |
| Return on Equity (ROE) | -28.95% | -44.76% | -26.21% | -52.27% | -50.85% |
| Return on Capital Employed (ROCE) | -26.18% | -40.08% | -23.68% | -46.43% | -29.41% |
| Return on Invested Capital (ROIC) | -25.46% | -38.77% | -23.13% | -44.91% | -28.54% |
| Return on Tangible Assets | -24.98% | -36.55% | -21.78% | -36.32% | -44.46% |
| Earnings Yield | -4.98% | -13.42% | -8.10% | -5.36% | -9.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 1.76 | 2.38 | 2.73 |
| Payables Turnover | 10.85 | 6.46 | 0.92 | 4.96 | 5.97 |
| Inventory Turnover | 2.05 | 1.37 | 0.26 | 2.75 | 0.37 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.09 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Cash Conversion Cycle | 144.19 | 209.99 | 1226.47 | 212.30 | 1054.74 |
| Days of Sales Outstanding | 0.00 | 0.00 | 207.91 | 153.23 | 133.88 |
| Days of Inventory Outstanding | 177.84 | 266.51 | 1415.88 | 132.59 | 982.02 |
| Days of Payables Outstanding | 33.65 | 56.52 | 397.31 | 73.53 | 61.16 |
| Operating Cycle | 177.84 | 266.51 | 1623.78 | 285.82 | 1115.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.24 | -2.49 | -2.58 | -1.55 | -1.56 |
| Free Cash Flow Per Share | -2.37 | -4.08 | -3.20 | -1.61 | -1.58 |
| Dividend Paid and CapEx Coverage Ratio | -17.05 | -1.58 | -4.14 | -27.56 | -91.85 |
| Capital Expenditure Coverage Ratio | -17.05 | -1.58 | -4.14 | -27.56 | -91.85 |
| Operating Cash Flow Coverage Ratio | -1.71 | -2.19 | -1.52 | -1.25 | -2.87 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -122.01 | -108.81 | -25.98 |
| Free Cash Flow Yield | -4.01% | -19.26% | -8.94% | -4.50% | -4.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -20.07 | -7.45 | -12.36 | -18.66 | -10.18 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 1695.08 | 2507.97 | 596.06 |
| Price-to-Book (P/B) Ratio | 5.81 | 3.33 | 3.24 | 9.75 | 5.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -24.94 | -5.19 | -11.19 | -22.24 | -22.69 |
| Price-to-Operating Cash Flow Ratio | -26.40 | -8.48 | -13.89 | -23.05 | -22.94 |
| Price-to-Earnings Growth (PEG) Ratio | -5.18 | 3.60 | -0.24 | 0.41 | -0.04 |
| Enterprise Value Multiple | -21.52 | -7.42 | -10.56 | -19.92 | -9.44 |
| Enterprise Value | 3.07B | 1.04B | 1.22B | 1.50B | 1.05B |
| EV to EBITDA | -21.52 | -7.42 | -10.56 | -19.92 | -9.44 |
| EV to Sales | 0.00 | 0.00 | 1294.99 | 2353.46 | 496.39 |
| EV to Free Cash Flow | -21.93 | -4.57 | -8.55 | -20.87 | -18.90 |
| EV to Operating Cash Flow | -23.21 | -7.47 | -10.61 | -21.63 | -19.10 |
| Tangible Book Value Per Share | 10.16 | 6.30 | 11.06 | 3.67 | 6.92 |
| Shareholders’ Equity Per Share | 10.19 | 6.35 | 11.07 | 3.67 | 6.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.02 | 0.01 | 0.06 |
| Net Income Per Share | -2.95 | -2.84 | -2.90 | -1.92 | -3.52 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 71.97 | 87.12 | 22.67 |
| SG&A to Revenue | 0.00 | 0.00 | 66.63 | 53.26 | 12.14 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 9.12 | 4.27 | 0.30 |
| Income Quality | 0.76 | 0.88 | 0.89 | 0.81 | 0.44 |
Currency in TWD
